StonvexLoading…
StonvexStonvexStonvexCore line items from IBTA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $342.39M | $367.25M | $320.04M | $210.70M |
Operating Income | $-841.00K | $27.93M | $56.00M | $-40.31M |
Net Income | $3.58M | $68.74M | $38.12M | $-54.86M |
EPS (Diluted) | $0.12 | $2.56 | $1.42 | $-6.33 |
Total Assets | $525.91M | $678.43M | $319.79M | Not available |
Total Liabilities | $238.26M | $221.15M | $291.86M | Not available |
Cash & Equivalents | $186.61M | $349.28M | $62.59M | $17.82M |
Free Cash Flow OCF − CapEx | $74.98M | $115.05M | $22.17M | $-57.28M |
Shares Outstanding | 30.10M | 0 | 9.21M | 8.67M |